SecBot SecBot
8-K ·Filed Nov 4, 2026

GERN

GERON CORP
MIXED
Impact 6/10
Horizonweeks Processed12d 19h ago SEC0001193125-26-446203
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The discontinuation of IMpactMF removes a major pipeline catalyst and makes Geron a single-product company dependent on LR-MDS. Watch for Q4 2026 revenue trajectory to assess whether the mid-to-high end of guidance is achievable, and monitor European launch execution and any pipeline re-evaluation.

DirectionMixed
Confidencehigh
Horizonweeks

RYTELO

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available (first commercial launch in Q3 2024)
Next catalyst
None dated

What to watchWatch the Q3 2026 earnings release on Nov 4, 2026 (consensus ~$60.4M revenue). The key question is whether RYTELO's revenue growth trajectory can accelerate from the ~11% QoQ pace, which would validate the revenue ramp thesis behind the $4+ analyst targets. The 7.39 days-to-cover short interest adds a squeeze potential if results surprise positively, but the shareholder lawsuit and high short volume ratio suggest significant skepticism about the commercial ramp.

Price Chart

Loading chart...

Executive Summary

Geron reported Q3 2026 RYTELO net product revenue of $60.1M, up 27% YoY from $47.2M, and achieved net income of $1.4M vs a net loss of $18.4M a year ago. The company reiterated 2026 RYTELO revenue guidance at the mid-to-high end of $220M-$240M and lowered operating expense guidance to $220M-$230M. However, the Phase 3 IMpactMF trial in myelofibrosis was discontinued after a DMC recommendation that it was unlikely to meet the overall survival endpoint, eliminating a key pipeline catalyst and increasing dependence on the LR-MDS indication.

Key Financial Metrics

EPS
$0.00
Revenue
$60.2M
est $60.4M · -0.3% · +27.4% YoY
Guidance
$220M-$240M (mid-to-high end)
maintained

Key Facts

  • Q3 2026 RYTELO net product revenue $60.1M, up 27% YoY from $47.2M and up 5% QoQ from Q2 2026
  • Net income of $1.4M in Q3 2026 vs net loss of $18.4M in Q3 2025
  • Total costs and operating expenses decreased to $54.4M from $61.1M YoY
  • 2026 RYTELO revenue guidance reiterated at mid-to-high end of $220M-$240M range
  • 2026 total operating expense guidance lowered to $220M-$230M from prior $230M-$240M
  • Phase 3 IMpactMF trial in JAK inhibitor R/R myelofibrosis discontinued after DMC recommendation that it was unlikely to meet the primary endpoint of overall survival
  • Cash, cash equivalents, restricted cash and marketable securities of $339.4M as of September 30, 2026
  • Initiated gated commercial launch in targeted European markets, with Germany expected by end of 2026

Financial Impact

Q3 revenue $60.1M, net income $1.4M, cash $339.4M

revenuenet incomeoperating expensescash position

Risk Factors

  • Phase 3 IMpactMF trial discontinued, no approval pathway for imetelstat in myelofibrosis
  • Company increasingly dependent on single indication (LR-MDS) for revenue
  • European commercial launch carries execution risk and reliance on third parties
  • Cash burn continues; cash of $339.4M may require future financing if revenue growth slows

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-446203
Document: d188608d8k.htm0001193125-26-446203
Document: 0001193125-26-446203-index-headers.html0001193125-26-446203
Document: 0001193125-26-446203-index.html0001193125-26-446203
Document: 0001193125-26-446203.txt0001193125-26-446203
8-K Data (Synthetic)0001193125-26-446203

Track record

11 reports on GERN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $0.9742 Now $0.9400 −3.51% settles Nov 17
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $0.9965 to $0.9419 Now $0.9400 −5.67% ▼ −5.48% −3.79% vs SPY
  3. Nov 4, 202612d ago 8-K Mixed 6/10 Viewing No price data
  4. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $1.08 to $1.02 Now $0.9400 −12.96% ▼ −5.56% −4.64% vs SPY
  5. Oct 28, 202619d ago 8-K Bearish 6/10 Entry $0.9462 to $0.9501 Now $0.9400 +0.66% ▼ −0.41% −5.14% vs SPY
  6. Oct 19, 202628d ago Press Release Neutral 2/10 Entry $1.24 to $1.16 Now $0.9400 −24.19% ▼ −6.85% −6.88% vs SPY
  7. Sep 18, 20268w ago Press Release Neutral 2/10 Entry $1.30 to $1.25 Now $0.9400 −27.69% ▼ −3.85% −2.83% vs SPY
  8. Apr 22, 202629w ago Press Release Neutral 1/10 Entry $1.55 to $1.52 Now $0.9400 −39.35% ▼ −2.26% −2.31% vs SPY
  9. Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $1.71 to $1.69 Now $0.9400 −45.03% ▼ −1.17% −4.69% vs SPY
  10. Mar 30, 202633w ago Court Ruling Neutral 2/10 Entry $1.41 to $1.74 Now $0.9400 −33.33% ▲ +23.40% +19.10% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026